What Impact Will Sept. 7 Australian Election Have On Pharma Industry?
This article was originally published in PharmAsia News
Executive Summary
Australia’s Federal Election is on Sept. 7, and both Medicines Australia and AusBiotech have been lobbying the Labor and the Liberal National parties to see what the incoming government can offer the pharmaceutical, medical device and biotechnology industries.
You may also be interested in...
Battle Over Deferred Drug Listings In Australia: Should Cost-Effective Drugs Always Be Funded?
A storm is brewing in the lead up to Australia's May 10 federal budget over the nation's Pharmaceutical Benefits Scheme, which acts as a single payer to subsidize drug prices and is administered by the government
Medicines Australia Negotiates Lower Off-patent Prices In Exchange For Level Prices For Innovative New Drugs In Newly Announced Federal Budget
PERTH, Australia - As part of the new federal budget announced May 11, Medicines Australia has negotiated price-saving measures with the Australian government that will cut prices on off-patent medicines in exchange for an assurance from the government that innovative prices on drugs will not be cut for four years
Considering Growth Options For Asian Biotechs: IPO Vs M&A
Going public via an IPO or being acquired are two ways that Asian biotech companies can grow their business, and some of the issues involved in both approaches come under discussion at a panel session at a recent conference in Singapore.